Literature DB >> 18003885

Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.

Linsheng Zhang1, Florence B Fried, Hong Guo, Alan D Friedman.   

Abstract

RUNX1/AML1 regulates lineage-specific genes during hematopoiesis and stimulates G1 cell-cycle progression. Within RUNX1, S48, S303, and S424 fit the cyclin-dependent kinase (cdk) phosphorylation consensus, (S/T)PX(R/K). Phosphorylation of RUNX1 by cdks on serine 303 was shown to mediate destabilization of RUNX1 in G2/M. We now use an in vitro kinase assay, phosphopeptide-specific antiserum, and the cdk inhibitor roscovitine to demonstrate that S48 and S424 are also phosphorylated by cdk1 or cdk6 in hematopoietic cells. S48 phosphorylation of RUNX1 paralleled total RUNX1 levels during cell-cycle progression, S303 was more effectively phosphorylated in G2/M, and S424 in G1. Single, double, and triple mutation of the cdk sites to the partially phosphomimetic aspartic acid mildly reduced DNA affinity while progressively increasing transactivation of a model reporter. Mutation to alanine increased DNA affinity, suggesting that in other gene or cellular contexts phosphorylation of RUNX1 by cdks may reduce transactivation. The tripleD RUNX1 mutant rescued Ba/F3 cells from inhibition of proliferation by CBFbeta-SMMHC more effectively than the tripleA mutant. Together these findings indicate that cdk phosphorylation of RUNX1 potentially couples stem/progenitor proliferation and lineage progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18003885      PMCID: PMC2214750          DOI: 10.1182/blood-2007-08-109702

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

Review 1.  Leukemogenesis by CBF oncoproteins.

Authors:  A D Friedman
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

2.  Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.

Authors:  S A Burel; N Harakawa; L Zhou; T Pabst; D G Tenen; D E Zhang
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.

Authors:  J Lou; W Cao; F Bernardin; K Ayyanathan; F J RauscherIII; A D Friedman
Journal:  Oncogene       Date:  2000-05-18       Impact factor: 9.867

4.  Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice.

Authors:  Yandan Yang; Weihua Wang; Rebecca Cleaves; Marianna Zahurak; Linzhao Cheng; Curt I Civin; Alan D Friedman
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

5.  PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.

Authors:  Gang Huang; Pu Zhang; Hideyo Hirai; Shannon Elf; Xiaomei Yan; Zhao Chen; Steffen Koschmieder; Yutaka Okuno; Tajhal Dayaram; Joseph D Growney; Ramesh A Shivdasani; D Gary Gilliland; Nancy A Speck; Stephen D Nimer; Daniel G Tenen
Journal:  Nat Genet       Date:  2007-11-11       Impact factor: 38.330

6.  Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms.

Authors:  Hee-Jun Wee; Gang Huang; Katsuya Shigesada; Yoshiaki Ito
Journal:  EMBO Rep       Date:  2002-09-13       Impact factor: 8.807

7.  TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice.

Authors:  Florence Bernardin; Yandan Yang; Rebecca Cleaves; Marianna Zahurak; Linzhao Cheng; Curt I Civin; Alan D Friedman
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

8.  RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.

Authors:  Kamaleldin E Elagib; Frederick K Racke; Michael Mogass; Rina Khetawat; Lorrie L Delehanty; Adam N Goldfarb
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

9.  c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.

Authors:  Florence Bernardin; Yandan Yang; Curt I Civin; Alan D Friedman
Journal:  Cancer Biol Ther       Date:  2002 Sep-Oct       Impact factor: 4.742

10.  AML1 stimulates G1 to S progression via its transactivation domain.

Authors:  Florence Bernardin; Alan D Friedman
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

View more
  30 in total

1.  Fragment of intron 5.2 of the human RUNX1 gene important for transcription activation is neither enhancer nor MAR-element.

Authors:  E N Markova; S V Razin; O L Kantidze
Journal:  Dokl Biochem Biophys       Date:  2012-03-15       Impact factor: 0.788

Review 2.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

3.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.

Authors:  Yasuhiko Kamikubo; Ling Zhao; Mark Wunderlich; Takeshi Corpora; R Katherine Hyde; Thomas A Paul; Mondira Kundu; Lisa Garrett; Sheila Compton; Gang Huang; Linda Wolff; Yoshiaki Ito; John Bushweller; James C Mulloy; P Paul Liu
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 4.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 5.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

6.  Tyrosyl phosphorylation toggles a Runx1 switch.

Authors:  Benjamin G Neel; Nancy A Speck
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

Review 7.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

8.  Runt-related Transcription Factor 1 (RUNX1) Binds to p50 in Macrophages and Enhances TLR4-triggered Inflammation and Septic Shock.

Authors:  Mao-Cai Luo; Si-Yuan Zhou; Dan-Ying Feng; Jun Xiao; Wei-Yun Li; Chun-Di Xu; Hong-Yan Wang; Tong Zhou
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

Review 9.  A role for RUNX1 in hematopoiesis and myeloid leukemia.

Authors:  Motoshi Ichikawa; Akihide Yoshimi; Masahiro Nakagawa; Nahoko Nishimoto; Naoko Watanabe-Okochi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

10.  The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.

Authors:  Ophélie Philipot; Véronique Joliot; Ouardia Ait-Mohamed; Céline Pellentz; Philippe Robin; Lauriane Fritsch; Slimane Ait-Si-Ali
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.